Showing 133–144 of 213 resultsSorted by latest
Pharma & Biotech
In Q3, Thermo Fisher’s pharma and biotech segment declined slightly, down in the low single digits, mainly due to the decrease in vaccine and therapy revenue.
LEQEMBI’s revenue in the U.S. is still below Biogen’s expectations, and the prescriber base hasn’t grown as much as anticipated.
Abbott achieved several key milestones in its biosimilars portfolio, with the first biosimilar set to launch in emerging markets by late 2025
Johnson & Johnson has recently acquired Shockwave and V-Wave in MedTech, along with Ambrx, Proteologix, and NM26 in Innovative Medicine.
ADMA is a commercial biopharmaceutical company focused on manufacturing, marketing, and developing speciality biologics to treat immunodeficient patients and others at risk for infections.
In the quarter, Royalty Pharma acquired royalties on six therapies, including one approved therapy and five in development.
MDT is at a pivotal moment in med-tech with its new PFA technology for AFib, which is rapidly changing disease treatment.
In May 2024, AstraZeneca completed a $140 million equity investment in Cellectis, a biotech company focused on gene editing.
Gilead recently reported positive results from the Phase 3 PURPOSE 1 trial of lenacapavir for HIV prevention, showing 100% efficacy with no infections in cisgender women
In the second quarter, Stryker (SYK) saw strong procedural volumes, driven by solid fundamentals and increased use of robotic-assisted surgery.
In the latest quarter, Abbott’s nutrition sales grew by 7.5%, fueled by strong performance in international adult nutrition and U.S. paediatric nutrition.
LLY is investing heavily in treating diseases, with 11 new molecules in clinical trials across various indications and several late – stage Phase 3 programs.